Advances in the treatment of small-cell lung cancer

Seminars in Respiratory and Critical Care Medicine

Volumn 32, Issue 1, 2011, Pages 94-101

  Kalemkerian, Gregory P ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

chemotherapy; prophylactic cranial irradiation; Small cell lung cancer

Indexed keywords

AMRUBICIN; CARBOPLATIN; CEDIRANIB; CI 779; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; MARIMASTAT; METHOTREXATE; NAVELBINE; PACLITAXEL; RI 11577; SULINDAC SULFONE; SUNITINIB; TANOMASTAT; TEMSIROLIMUS; TENIPOSIDE; THALIDOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; LUNG SMALL CELL CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; CELL SURVIVAL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SMALL CELL LUNG CARCINOMA; SURVIVAL;

EID: 79954574461     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0031-1272873     Document Type: Article

References (59)

1. Navada S, Lai P, Schwartz A G., Kalemkerian G P. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results database. [abstract 7082] J Clin Oncol 2006 24 18 Suppl 384s
2. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006 24 28 4539-4544 (Pubitemid 46630948)
3. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 1973 4 2 31-42
4. Goldstraw P, Crowley J J., Chansky K et al, International Association for the Study of Lung Cancer International Staging Committee Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007 2 8 706-714 (Pubitemid 47357522)
5. Shepherd F A., Crowley J, Van Houtte P et al. The IASLC Lung Cancer Staging Project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007 2 1067-1077 (Pubitemid 350307898)
6. Kalemkerian G P., Akerley W, Downey R J. et al. Small cell lung cancer. J Natl Compr Canc Netw 2008 6 3 294-314 (Pubitemid 351488824)
7. Bradley J D., Dehdashti F, Mintun M A., Govindan R, Trinkaus K, Siegel B A. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004 22 16 3248-3254 (Pubitemid 41103679)
8. Brink I, Schumacher T, Mix M et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004 31 12 1614-1620 (Pubitemid 40104607)
9. Hauber H P., Bohuslavizki K H., Lund C H., Fritscher-Ravens A, Meyer A, Pforte A. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest 2001 119 3 950-954 (Pubitemid 32197670)
10. Kamel E M., Zwahlen D, Wyss M T., Stumpe K D., von Schulthess G K., Steinert H C. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003 44 12 1911-1917 (Pubitemid 40022136)
11. Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, Rogers J S. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008 9 1 30-34 (Pubitemid 351251598)
12. Pignon J P., Arriagada R, Ihde D C. et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992 327 23 1618-1624
13. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992 10 6 890-895
14. Fried D B., Morris D E., Poole C et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004 22 23 4837-4845
15. Turrisi A T. III, Kim K, Blum R et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999 340 4 265-271 (Pubitemid 29063268)
16. Bonner J A., Sloan J A., Shanahan T G. et al. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma. J Clin Oncol 1999 17 9 2681-2691 (Pubitemid 29415224)
17. Aupérin A, Arriagada R, Pignon J P. et al, Prophylactic Cranial Irradiation Overview Collaborative Group. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med 1999 341 7 476-484 (Pubitemid 29372887)
18. Arriagada R, Le Chevalier T, Borie F et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995 87 3 183-190
19. Patel S, Macdonald O K., Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer 2009 115 4 842-850
20. Slotman B, Faivre-Finn C, Kramer G et al, EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007 357 7 664-672 (Pubitemid 47267236)
21. Slotman B J., Mauer M E., Bottomley A et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol 2009 27 1 78-84
22. Le Péchoux C, Dunant A, Senan S et al, Prophylactic Cranial Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009 10 5 467-474
23. Greco F A., Oldham R K. Clinical management of patients with small cell lung cancer. In: Greco F A. Oldham R K. Bunn P A. eds. Small Cell Lung Cancer. New York Grune & Stratton 1981 353-379
24. Lowenbraun S, Bartolucci A, Smalley R V., Lynn M, Krauss S, Durant J R. The superiority of combination chemotherapy over single agent chemotherapy in small cell lung carcinoma. Cancer 1979 44 2 406-413 (Pubitemid 10220121)
25. Ihde D C. Chemotherapy of lung cancer. N Engl J Med 1992 327 20 1434-1441
26. Evans W K., Shepherd F A., Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985 3 11 1471-1477 (Pubitemid 16246758)
27. Fukuoka M, Furuse K, Saijo N et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991 83 12 855-861
28. Roth B J., Johnson D H., Einhorn L H. et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992 10 2 282-291
29. Sundstrøm S, Bremnes R M., Kaasa S et al, Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002 20 24 4665-4672 (Pubitemid 36025283)
30. Pujol J L., Carestia L, Daurès J P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 2000 83 1 8-15
31. Mascaux C, Paesmans M, Berghmans T et al, European Lung Cancer Working Party (ELCWP). A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 2000 30 1 23-36
32. Chute J P., Chen T, Feigal E, Simon R, Johnson B E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999 17 6 1794-1801 (Pubitemid 29269249)
33. Noda K, Nishiwaki Y, Kawahara M et al, Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002 346 2 85-91 (Pubitemid 34438898)
34. Hanna N, Bunn P A. Jr, Langer C et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006 24 13 2038-2043 (Pubitemid 46622112)
35. Lara P N. Jr, Natale R, Crowley J et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009 27 15 2530-2535
36. Eckardt J R., von Pawel J, Papai Z et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 2006 24 13 2044-2051 (Pubitemid 46622113)
37. Thomas P, Castelnau O, Paillotin D et al. Phase II trial of paclitaxel and carboplatin in metastatic small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie study. J Clin Oncol 2001 19 5 1320-1325 (Pubitemid 32202536)
38. Lyss A P., Herndon J E. II, Lynch T J. Jr et al. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clin Lung Cancer 2002 3 3 205-210 discussion 211-212 (Pubitemid 34213651)
39. Hanna N H., Einhorn L H. Small-cell lung cancer: state of the art. Clin Lung Cancer 2002 4 2 87-94 (Pubitemid 35174865)
40. Postmus P E., Berendsen H H., van Zandwijk N, Splinter T A., Burghouts J T., Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol 1987 23 9 1409-1411 (Pubitemid 18006732)
41. Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol 1987 23 11 1697-1699 (Pubitemid 18044647)
42. O'Brien M ER, Ciuleanu T E., Tsekov H et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006 24 34 5441-5447 (Pubitemid 46623178)
43. von Pawel J, Schiller J H., Shepherd F A. et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999 17 2 658-667 (Pubitemid 29075255)
44. Yana T, Negoro S, Takada M et al, West Japan Thoracic Oncology Group. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. Invest New Drugs 2007 25 3 253-258 (Pubitemid 46774694)
45. Ohe Y, Negoro S, Matsui K et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 2005 16 3 430-436 (Pubitemid 40458320)
46. Onoda S, Masuda N, Seto T et al, Thoracic Oncology Research Group Study 0301. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006 24 34 5448-5453 (Pubitemid 46623179)
47. Igawa S, Yamamoto N, Ueda S et al. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. J Thorac Oncol 2007 2 8 741-744 (Pubitemid 47357529)
48. Ettinger D S., Jotte R, Lorigan P et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010 28 15 2598-2603
49. Shimokawa T, Shibuya M, Kitamura K et al. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol 2009 14 1 63-69
50. Inoue A, Sugawara S, Yamazaki K et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008 26 33 5401-5406
51. Eckardt J R., Bentsion D L., Lipatov O N. et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 2009 27 12 2046-2051
52. Spigel D R., Hainsworth J D., Lane C M., Clark B, Burris H A., Greco F A. Phase II trial of vinflunine in relapsed small cell lung cancer. J Thorac Oncol 2010 5 6 874-878
53. Ciuleanu T, Samarzjia M, Demidchik Y et al. Randomized phase III study (SPEAR) of picoplatin plus best supportive care (BSC) or BSC alone in patients with SCLC refractory or progressive within 6 months after first-line platinum-based chemotherapy. [abstract 7002] J Clin Oncol 2010 28 15 Suppl 515s
54. Rudin C M., Hann C L., Peacock C D., Watkins D N. Novel systemic therapies for small cell lung cancer. J Natl Compr Canc Netw 2008 6 3 315-322 (Pubitemid 351488825)
55. Skarlos D V., Samantas E, Kosmidis P et al. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994 5 7 601-607 (Pubitemid 24283096)
56. Johnson D H. The guard dies, it does not surrender! progress in the management of small-cell lung cancer? J Clin Oncol 2002 20 24 4618-4620 (Pubitemid 36025276)
57. Seifter E J., Ihde D C. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988 15 3 278-299
58. Aisner J, Alberto P, Bitran J et al. Role of chemotherapy in small cell lung cancer: a consensus report of the International Association for the Study of Lung Cancer workshop. Cancer Treat Rep 1983 67 1 37-43 (Pubitemid 13144172)
59. Lassen U N., Hirsch F R., Osterlind K, Bergman B, Dombernowsky P. Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? Lung Cancer 1998 20 3 151-160 (Pubitemid 28356831)